Back

Notification report


Full notification file


General information

Notification Number
B/ES/17/02

Member State to which the notification was sent
Spain

Date of acknowledgement from the Member State Competent Authority
13/03/2017

Title of the Project
Phase 3 study of ADXS11-001 administered following chemoradiation as adjuvant treatment for high risk locally advanced cervical cancer AIM2CERV (Advaxis IMmunotherapy 2 prevent CERVical recurrence)

Proposed period of release:
01/08/2017 to 01/08/2022

Name of the Institute(s) or Company(ies)
Advaxis Inc., 305 College Road Est
Princeton, NJ 08540, USA;


3. Is the same GMO release planned elsewhere in the Community?
Yes:
Spain; Netherlands; Poland; Romania;

Has the same GMO been notified elsewhere by the same notifier?
No

GMO characterization

GMO is a:
Bacterium

Identity of the GMO:
The GMO is an attenuated Listeria monocytogenes strain which has been engineered to express the tLLO-E7 fusion protein.The E7 protein sequence was derived from Human Papilloma Virus 16. The Listeria monocytogenes strain is named axalimogene filolisbac, and is also known as ADXS11-001. Axalimogene filolisbac is a clinical drug product administered to patients for cancer treatment.

Information relating to the recipient or parental organisms from wich the GMO is derived
Common NameGenusSpeciesSubspeciesStrainPathovar
XFL7Listeriamonocytogenes--serovar 1/2a

European Commission administrative information

Consent given by the Member State Competent Authority:
Not known